Comparative effectiveness and safety of steroids, Aminosalicylates, and biological drugs in patients with inflammatory bowel diseases

Background: Crohn's disease and ulcerative colitis are forms of inflammatory bowel disease (IBD). Several drugs aimed at controlling intestinal inflammation have been developed.Aim of the study: To compare the effectiveness and safety of Steroids, 5’ASA, Infliximab, and Adalimumab in patients with Ulcerative colitis (UC) or Crohn’s disease (CD).Patients and methods: A multicenter cross-sectional study was conducted among 174 patients with IBD. Patients were classified into four groups according to treatment regimen.Results: 50 patients (28.7%) with CD and 124 (71.3%) with UC, 46 patients (26.4%) showed lesions confined to the recto-sigmoid area, 38 patients (21.8%) with left-sided lesions, 53(29.5%) with pancolitis, and 37(21.3%) with ileal or Small intestinal involvement. 50(28.7%) patients with mild activity, 86(49.7%) with moderate activity and 38(21.8%) with severe activity. There was a statistically significant difference in pre- and post-Mayo treatment scores for UC (P=0.06 and 0.002, respectively). In CD, there was a statistically significant difference in pre- and post-treatment Crohn’s disease activity index (CDAI), degree, and percent change (P=0.005, 0.003, 0.002, 0.0006, respectively). Primary drug-non response and relapse were more pronounced in Group (I ), 55%and 62.1%, and 0% and 9%, respectively, in Group (IV) (P